UMN Pharma begins preparations for construction of a manufacturing facility for UMN-0501, a pandemic influenza vaccine manufactured using a novel cell culture technique.

UMN Pharma Inc. announced that it has reached a construction agreement with IHI Plant Engineering Corporation, an affiliate of IHI Corporation. This is the first step toward the construction of a facility to manufacture UMN-0501, UMN's pandemic influenza vaccine under development, produced using a cell culture technique.